Meeting
2019 Genitourinary Cancers Symposium
Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.
Authors
Nicholas J. Vogelzang
Comprehensive Cancer Centers of Nevada, Las Vegas, NV
Nicholas J. Vogelzang , Joshua Jemison McFarlane , Mark D. Kochenderfer , Ana M. Molina , Edward Arrowsmith , Todd Michael Bauer , Ralph J. Hauke , Rohit Jain , Bradley G. Somer , Elaine Tat Lam , Gurjyot K. Doshi , Vijay Gunuganti , Joshua Zhang , Huanyu Zhao , Jennifer Johansen , Scott S. Tykodi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02596035
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 562)
DOI
10.1200/JCO.2019.37.7_suppl.562
Abstract #
562
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.
First Author: Arlene O. Siefker-Radtke
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of ONO-4578 plus nivolumab in metastatic colorectal cancer.
First Author: Akihito Kawazoe
Poster
2022 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
First Author: Luis G. Paz-Ares
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).
First Author: Inna Markovna Chen